We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides

By LabMedica International staff writers
Posted on 23 Apr 2026

Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. More...

Nearly 20 million new cases are diagnosed each year, and traditional artificial intelligence (AI) tools require massive datasets and repeated retraining for each tumor type. These hurdles slow deployment, particularly across diverse clinical settings. Researchers now introduce a plug-and-play pathology system that classifies multiple cancers from only a few annotated slides.

At The Hong Kong University of Science and Technology (HKUST), investigators developed PRET (Pan-cancer Recognition without Example Training), a pathology analysis system designed to recognize multiple tumor types from minimal samples without additional training. Positioned as a plug-and-play tool for digital pathology, PRET targets routine diagnostic tasks that can burden laboratory workflows.

The system applies “in-context learning,” a strategy adapted from natural language processing, to whole-slide image analysis. During inference, PRET adapts to new cancer types and tasks by referencing just one to eight annotated tumor slides, rather than relying on task-specific fine-tuning. The approach is described as supporting cancer screening, tumor subtyping, tumor segmentation, and lymph node metastasis detection.

Validation drew on 23 international benchmark datasets from institutions in the Chinese Mainland, the United States, and the Netherlands, encompassing 18 cancer types and multiple diagnostic tasks. PRET demonstrated stable, robust generalizability across different populations and regions with varying medical resources. The evaluation addressed clinically relevant endpoints across settings.

Across these datasets, the system outperformed existing methods in 20 tasks. Its area under the curve (AUC), a measure of diagnostic accuracy, exceeded 97% in 15 tasks; results included an AUC of 100% in colorectal cancer screening and 99.54% in esophageal squamous cell carcinoma tumor segmentation. For lymph node metastasis detection, PRET achieved an AUC of approximately 98.71% using only eight slide samples, surpassing the average performance of 11 pathologists, whose AUC averaged approximately 81%.

The study is published in Nature Cancer. Collaborating institutions included Guangdong Provincial People’s Hospital and Harvard Medical School. The team plans to further enhance performance and extend applications to genetic mutation prediction and patient prognosis assessment.

“The core value of the PRET system lies in breaking down the traditional barriers of ‘massive data and repetitive training,’ enabling AI-powered pathology systems to be applied in real clinical settings at lower cost and with greater flexibility. This not only helps alleviate the workload pressure faced by pathologists, but also has the potential to improve access to cancer diagnosis in underserved regions,” said Prof. Li Xiaomeng, Assistant Professor of the Department of Electronic and Computer Engineering and Associate Director of the Center for Medical Imaging and Analysis, The Hong Kong University of Science and Technology.

“Through this ‘plug-and-play’ system, we hope that advanced and precise AI-powered diagnostic services can transcend geographical and resource constraints, thereby promoting global health care equity,” said Prof. Li Xiaomeng.

Related Links
HKUST


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.